Interní Med. 2018; 20(3): 127-130 | DOI: 10.36290/int.2018.023

Are there caveats in a treatment of CAD?

doc. MUDr. Tomáš Kovárník, Ph.D.
II. interní klinika – klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Authors summarise possible caveats in a treatment of coronary artery disease (CAD). In the first line they underline proper indicationfor coronary revascularization based on a prove of myocardial ischemia. Further important point is adequate lipid-loweringtherapy leading to atherosclerosis regression. Lipid-lowering therapy is frequently used in insufficient doses not leading to therequired target levels for secondary prevention in the patients with CAD. But only those targets levels lead to regression ofcoronary atherosclerosis and then to decrease of the risk for ischemic coronary events.

Keywords: coronary artery disease, coronary atherosclerosis, revascularization, lipid-lowering therapy

Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kovárník T. Are there caveats in a treatment of CAD? Interní Med. 2018;20(3):127-130. doi: 10.36290/int.2018.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Piccini JP, Horton JR, Shaw LK, Al-Khatib SM, Lee KL, Iskandrian AE, Borges-Neto S. Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death. Circ Cardiovasc. Imaging 2008; 3: 180-188. Go to original source... Go to PubMed...
    2. Boden W, O'Rourke R, Teo K, Hartigan P, Maron D, Kostuk W, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007; 356: 1503-1516. Go to original source... Go to PubMed...
    3. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391: 31-40. Go to original source... Go to PubMed...
    4. Varvařovský I. Léčba stabilních forem ICHS - medikamentózní léčba nebo PCI: studie COURAGE a SWISI II. Interv Akut Kardiol 2007; 6: 115-116.
    5. De Bruyne B, Pijls N, Kalesan B, Barbato E, Tonino P, Piroth Z, et al. Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease. N Engl J Med. 2012; 367: 991-1001. Go to original source... Go to PubMed...
    6. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283-1291. Go to original source... Go to PubMed...
    7. Hachamovitch R, Rozanski A, Shaw L, Stone G, Thomson L, Friedman J, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. European Heart Journal 2011; 32: 1012-1024. Go to original source... Go to PubMed...
    8. Johnson NP, Kirkeelde RL, Gould KL. Coronary anatomy to predict physiology: fundamental limits. Circ Cardiovasc Imaging 2013; 6: 817-832. Go to original source... Go to PubMed...
    9. Kovárník T, Červinka P, Mates M, Bernát I, Branny M, Horák D, et al. Používání invazivních zobrazovacích (optická koherenční tomografie, intravaskulární ultrazvuk) a funkčních (frakční průtoková rezerva) metod v intervenční kardiologii. Odborné stanovisko České asociace intervenční kardiologie a České kardiologické společnosti. Cor et Vasa 20176: 749-751.
    10. Nicholls S, Hsu A, Wolski K, et al. Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical Outcome. J Am Coll Cardiol, 2010; 55: 2399-407. Go to original source... Go to PubMed...
    11. Nissen S, Tuzscu M, Schoenhagen P, et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclertosis. JAMA 2004; 291: 1071-1080. Go to original source... Go to PubMed...
    12. Cannon Ch, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. NEJM 2015; 372: 2378-2397. Go to original source... Go to PubMed...
    13. Murphy S, Cannon Ch, Blazing M, Giugliano R, White J, Lokhnygina Y, et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. J Am Coll Cardiol 2016; 67: 353-61. Go to original source... Go to PubMed...
    14. Hoe E, Hegele R. Lipid management in diabetes with a focus on emerging therapies. Canadian Journal of Diabetes. 2015; 39: 2183-S190. Go to original source... Go to PubMed...
    15. Lee Y, Tsujita K, Gonzalez J, Kramer Ch, Kovarnik T, et al. Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis Namki Hong. Endocrinology and metabolism (Seoul) 2018 in press.
    16. Masuda J,Tanigawa T, Yamada T, et al. Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease. Int Heart J 2015; 56: 278-285. Go to original source... Go to PubMed...
    17. Kovarnik T, Mintz GS, Skalicka H, et al. Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration. Circ J. 2012; 76: 176-183. Go to original source... Go to PubMed...
    18. Nicholls S, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016; 316: 2373-2384. Go to original source... Go to PubMed...
    19. Sabatine M, Giugliano R, Keech A, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376: 1713-1722. Go to original source... Go to PubMed...
    20. Steg P. Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab - ODYSSEY OUTCOMES. Prezentace na kongresu ACC 2018, Orlando, USA
    21. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. JACC 2018; 71: e121s-e248. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.